Appropriately aggregate holistic technologies via accurate expertise. Intrinsicly strategize worldwide initiatives and premium methodologies.
Comparison of short- and long-term humoral immune responses to pneumococcal polysaccharide and glycoconjugate vaccines in an HIV-infected population.
Faustini SE. et al, (2024), The Journal of infection, 89
Evaluation of a Quadrivalent <i>Shigella flexneri</i> Serotype 2a, 3a, 6, and <i>Shigella sonnei</i> O-Specific Polysaccharide and IpaB MAPS Vaccine.
Boerth EM. et al, (2024), Vaccines, 12
Optimizing Vaccine Trials for Enteric Diseases: The Enterics for Global Health (EFGH) Shigella Surveillance Study.
Vannice K. et al, (2024), Open forum infectious diseases, 11, S1 - S5
Clinical and regulatory development strategies for Shigella vaccines intended for children younger than 5 years in low-income and middle-income countries.
Giersing BK. et al, (2023), The Lancet. Global health, 11, e1819 - e1826
The 2022 Vaccines Against Shigella and Enterotoxigenic Escherichia coli (VASE) Conference: Summary of breakout workshops.
Baqar S. et al, (2023), Vaccine
A genomic appraisal of invasive Salmonella Typhimurium and associated antibiotic resistance in sub-Saharan Africa.
Van Puyvelde S. et al, (2023), Nat Commun, 14
Salmonella Combination Vaccines: Moving Beyond Typhoid
MacLennan CA. et al, (2023), Open Forum Infectious Diseases, 10, S58 - S66
Efficient Autotransporter-Mediated Extracellular Secretion of a Heterologous Recombinant Protein by Escherichia coli.
Beriotto I. et al, (2023), Microbiology spectrum, 11
Severe anaemia, iron deficiency, and susceptibility to invasive bacterial infections
Abuga KM. et al, (2023), Wellcome Open Research, 8, 48 - 48
Consequences of Shigella infection in young children: a systematic review.
Libby TE. et al, (2023), Int J Infect Dis
Complementary measurement of nontyphoidal Salmonella-specific IgG and IgA antibodies in oral fluid and serum.
Elias SC. et al, (2023), Heliyon, 9
Exploring the variables influencing the immune response of traditional and innovative glycoconjugate vaccines.
Micoli F. et al, (2023), Frontiers in molecular biosciences, 10
Immune responses to Neisseria gonorrhoeae and implications for vaccine development.
Belcher T. et al, (2023), Frontiers in immunology, 14
Vi polysaccharide and conjugated vaccines afford similar early, IgM or IgG-independent control of infection but boosting with conjugated Vi vaccines sustains the efficacy of immune responses
Jossi SE. et al, (2023), Frontiers in Immunology, 14
Threshold protective levels of serum IgG to Shigella lipopolysaccharide: re-analysis of Shigella vaccine trials data.
Cohen D. et al, (2022), Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
Impact and Control of Sugar Size in Glycoconjugate Vaccines.
Stefanetti G. et al, (2022), Molecules (Basel, Switzerland), 27